Importance Few treatments are available for patients with glucocorticoid-dependent
polymyalgia rheumatica. IL-6 antagonists may reduce disease activity in patients with active …

Objective To assess the efficacy and safety of modified-release (MR) versus immediate-
release (IR) prednisone in newly diagnosed glucocorticoid (GC)-naïve patients with …

Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease affecting people aged
50 years or older. PMR usually improves with glucocorticoids (GC), with rapid resolution of …

Abstract The last British Society for Rheumatology (BSR) guideline on PMR was published
in 2009. The guideline needs to be updated to provide a summary of the current evidence …

Background Polymyalgia rheumatica is the second most common inflammatory rheumatic
disease of people> 50 years. Glucocorticoid therapy is highly effective, but many patients …

Objective: To provide evidence-based up-to-date recommendations for the management of
patients with a definite diagnosis of polymyalgia rheumatica (PMR). Methods: A systematic …

Objectives To explore current management practices for PMR by general practitioners (GPs)
and rheumatologists including implications for clinical trial recruitment. Methods An English …

Objective. The Outcome Measures in Rheumatology (OMERACT) polymyalgia rheumatica
(PMR) working group aims to develop a core set of outcome measures to be used in clinical …

ABSTRACT Introduction: Polymyalgia rheumatica (PMR), a common disease in individuals
older than 50 in the western world, is characterized by bilateral inflammatory pain involving …

Aim This study aimed to identify predictive factors of glucocorticoid (GC)‐free remission in
patients with polymyalgia rheumatica (PMR) treated with prednisolone (PSL). Method …